查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1917793

临床试验诊断影像市场－2026-2031年预测

Clinical Trial Imaging Market - Forecast from 2026 to 2031
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 144 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

临床试验影像诊断市场预计将从 2025 年的 17.32 亿美元成长到 2031 年的 26.07 亿美元，复合年增长率为 7.05%。

临床试验诊断影像市场是生命科学产业中重要且不断成长的细分市场，是现代药物研发和疗效评估的关键工具。该市场利用磁振造影（MRI）、电脑断层扫描（CT）、正子断层扫描（PET）和超音波等先进影像技术，为临床研究中疾病进展和治疗效果提供客观、定量和纵向数据。其成长受多种因素驱动，包括临床试验复杂性的增加、慢性病盛行率的上升以及整个产业的大规模投资，这些因素共同作用，使诊断影像成为精准高效临床研究的基础。

市场扩张的关键驱动因素是生物技术产业对以影像为中心的临床研究的大量且不断增长的投资。医疗保健成本的上升和对创新治疗方法的关注推动了生物技术公司的激增，这直接促进了对先进影像终点的需求。从产业领导企业到新兴企业，都在整合影像通讯协定，以降低研发风险、验证生物学概念验证并满足新治疗领域的监管要求。这一趋势标誌着影像技术正从辅助工具转变为临床试验设计的基本组成部分，尤其是在复杂的生物製剂和标靶治疗。

全球癌症负担日益加重，持续推动市场需求。肿瘤临床试验越来越依赖先进的成像技术进行患者分层、评估治疗反应以及检验新的作用机制。随着精准医疗和标靶治疗的兴起，精确的影像生物标记对于监测肿瘤生物学的细微变化至关重要，其应用也从简单的解剖学测量发展到功能性和分子成像。影像技术在表征癌症表型和量化治疗效果方面发挥关键作用，这使其在大多数肿瘤药物研发项目中占据核心地位，而这一趋势仍在不断发展。

此外，包括心血管疾病、代谢性疾病、神经系统疾病和肾臟疾病在内的多种慢性疾病的日益普遍，正在加速影像学在临床试验中的应用。对于这些疾病，影像学提供了一种非侵入性方法，可用于早期检测、精准诊断以及灵敏地监测疾病的进展或消退。研究人员可以观察器官和组织随时间推移发生的病理变化，从而深入了解药物作用机制和治疗效果，尤其对于那些传统终点指标进展缓慢或主观性较强的疾病而言。这种能力对于开发治疗长期慢性疾病的有效治疗方法至关重要。

此外，全球临床研究计划规模的不断扩大和复杂性的提升进一步推动了市场发展。在各个治疗领域，采用影像学通讯协定的临床试验数量显着增加。这得归功于定量影像生物标记标准化以及临床前和临床影像学调查方法优化工作的发展。专注于产生可靠且可重复的影像学数据，能够提高试验质量，加快决策速度，并增加获得监管部门核准的可能性。将影像学整合到大规模、跨国临床试验中，进一步证实了其在产生高度精确证据方面的既有价值。

从区域来看，北美预计将继续占据临床试验影像市场的主导地位。这一主导地位得益于多项结构性优势，包括製药和生物技术公司的高度集中、医疗保健和研究领域的巨额投入、需要先进治疗研究的慢性疾病的高发生率，以及由临床研究机构 (CRO) 和专业影像服务提供者组成的强大生态系统。持续的技术进步和支持创新研究设计的法规结构进一步巩固了该地区在促进和传播市场标准方面的关键作用。

在竞争格局中，专业服务供应商和技术公司为临床试验提供端到端的影像解决方案。这些解决方案涵盖核心影像检查实验室服务和集中式影像分析，以及开发整合人工智慧 (AI) 和机器学习技术的专有软体平台进行资料分析。各公司凭藉其在治疗领域的专业知识、定量成像技术能力以及确保全球临床试验符合监管要求的能力而脱颖而出。这些服务对于以标准化和盲法的方式管理影像撷取、传输、分析和解读等复杂流程至关重要。

总之，临床试验影像市场正经历持续成长，其根本驱动力在于药物研发需求的不断演变。标靶治疗的融合、慢性疾病中对客观生物标记的需求以及生物技术产业的策略投资，共同巩固了影像技术在临床研究中作为关键成功因素的地位。未来市场的发展将受到定量影像生物标记进步、人工智慧在高级数据分析中的应用以及全球研究网络持续推进标准化需求的影响。对业界专家而言，重点仍是利用影像技术提高试验效率、展现明确的治疗价值并加速新治疗方法惠及病患。

本报告的主要优势：

  • 深入分析：提供对主要和新兴地区的深入市场洞察，重点关注客户群、政府政策和社会经济因素、消费者偏好、垂直行业和其他细分市场。
  • 竞争格局：了解全球主要参与者的策略倡议，并了解透过正确的策略实现市场渗透的潜力。
  • 市场驱动因素与未来趋势：探索推动市场的动态因素和关键趋势，以及它们将如何塑造未来的市场发展。
  • 可操作的建议：利用这些见解，在快速变化的环境中做出策略决策，并发现新的商机和收入来源。
  • 受众广泛：适用于Start-Ups、研究机构、顾问公司、中小企业和大型企业，且经济实惠。

企业如何使用我们的报告？

产业与市场分析、机会评估、产品需求预测、打入市场策略、地理扩张、资本投资决策、法规结构及影响、新产品开发、竞争情报

研究范围：

  • 2021年至2025年的历史数据和2026年至2031年的预测数据
  • 成长机会、挑战、供应链前景、法规结构与趋势分析
  • 竞争定位、策略和市场占有率分析
  • 按业务板块和地区（包括国家）分類的收入和预测评估
  • 公司概况（策略、产品、财务资讯、关键发展等）

目录

第一章执行摘要

第二章 市场概览

  • 市场概览
  • 市场定义
  • 调查范围
  • 市场区隔

第三章 商业情境

  • 市场驱动因素
  • 市场限制
  • 市场机会
  • 波特五力分析
  • 产业价值链分析
  • 政策与法规
  • 策略建议

第四章 技术展望

第五章 依产品类型分類的临床试验影像诊断市场

  • 介绍
  • 解决方案
  • 服务

第六章：依技术分類的临床试验影像诊断市场

  • 介绍
  • 磁振造影（MRI）
  • CT（电脑断层扫描）
  • PET（正子断层扫描）
  • 超音波
  • 其他的

第七章 临床试验影像诊断市场（依应用领域划分）

  • 介绍
  • 肿瘤学
  • 循环系统
  • 胃肠病学
  • 神经病学
  • 儿童
  • 其他的

第八章：按最终用户分類的临床试验诊断影像市场

  • 介绍
  • 医院和诊所
  • 诊断中心
  • 其他的

第九章：按地区分類的临床试验影像诊断市场

  • 介绍
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 西班牙
    • 其他的
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 以色列
    • 其他的
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 韩国
    • 印尼
    • 泰国
    • 其他的

第十章 竞争格局与分析

  • 主要企业和策略分析
  • 市占率分析
  • 合併、收购、协议和合作
  • 竞争对手仪錶板

第十一章 公司简介

  • IXICO plc
  • Resonance Health
  • Radiant Sage LLC
  • Medpace Holdings, Inc
  • WCG Clinical
  • Koninklijke Philips NV
  • Median Technologies
  • Perceptive
  • Clario
  • Qmenta

第十二章附录

  • 货币
  • 先决条件
  • 基准年和预测年时间表
  • 相关人员的主要收益
  • 调查方法
  • 简称
简介目录
Product Code: KSI061615767

Clinical Trial Imaging Market is projected to expand at a 7.05% CAGR, attaining USD 2.607 billion in 2031 from USD 1.732 billion in 2025.

The clinical trial imaging market is a critical and expanding segment within the life sciences industry, serving as an indispensable tool for modern drug development and therapeutic evaluation. This market encompasses the use of advanced imaging modalities-such as MRI, CT, PET, and ultrasound-to provide objective, quantitative, and longitudinal data on disease progression and treatment efficacy within clinical research. Its growth is propelled by a confluence of factors including the rising complexity of clinical trials, the increasing prevalence of chronic diseases, and significant sector-wide investments, positioning imaging as a cornerstone of precise and efficient clinical research.

A primary driver of market expansion is the substantial and growing investment from the biotechnology sector into imaging-centric clinical research. The proliferation of biotechnology companies, fueled by increased healthcare expenditure and a focus on innovative therapies, has directly increased demand for sophisticated imaging endpoints. These companies, ranging from established leaders to emerging entities, are integrating imaging protocols to de-risk development, demonstrate biological proof-of-concept, and satisfy regulatory requirements for novel therapeutic classes. This trend signifies a shift where imaging is no longer a supplementary tool but a foundational component of clinical trial design, particularly for complex biological and targeted therapies.

The escalating global burden of cancer remains a powerful catalyst for market demand. Oncology clinical trials increasingly rely on advanced imaging for patient stratification, treatment response assessment, and the evaluation of novel mechanisms of action. The shift towards personalized medicine and targeted therapies necessitates precise imaging biomarkers to monitor subtle changes in tumor biology, moving beyond simple anatomic measurements to functional and molecular imaging. The critical role of imaging in characterizing cancer phenotypes and quantifying therapeutic impact ensures its central position in the vast majority of oncological drug development programs, a trend that continues to intensify.

Furthermore, the growing prevalence of a broad spectrum of chronic diseases-including cardiovascular, metabolic, neurological, and renal disorders-is accelerating the adoption of clinical trial imaging. For these conditions, imaging provides non-invasive methods for early detection, precise diagnosis, and sensitive monitoring of disease progression or regression. It enables researchers to visualize pathological changes in organs and tissues over time, offering invaluable insights into a drug's mechanism of action and therapeutic benefit in diseases where traditional endpoints may be slow to manifest or subjective. This capability is crucial for developing effective interventions for long-term chronic conditions.

The market is further stimulated by the increasing scale and sophistication of global clinical research projects. There is a marked rise in the number of trials incorporating imaging protocols across diverse therapeutic areas. This is supported by initiatives aimed at standardizing quantitative imaging biomarkers and optimizing imaging methodologies for both preclinical and clinical settings. The focus on generating robust, reproducible imaging data enhances trial quality, facilitates faster decision-making, and improves the likelihood of regulatory success. The integration of imaging into large-scale, multinational trials underscores its established value in generating high-fidelity evidence.

From a regional perspective, North America is projected to maintain a dominant share of the clinical trial imaging market. This leadership is attributed to several structural advantages: a high concentration of pharmaceutical and biotechnology corporations, substantial healthcare and research expenditure, a significant prevalence of chronic diseases necessitating advanced therapeutic research, and a robust ecosystem of clinical research organizations (CROs) and imaging specialty providers. Continuous technological advancements and supportive regulatory frameworks for innovative trial designs further consolidate the region's pivotal role in driving market standards and adoption.

The competitive landscape features specialized service providers and technology companies that offer end-to-end imaging solutions for clinical trials. These range from core imaging laboratory services and centralized image analysis to the development of proprietary software platforms incorporating artificial intelligence and machine learning for data analytics. Companies are distinguished by their therapeutic area expertise, technological capabilities in quantitative imaging, and their ability to ensure regulatory compliance across global trials. Their services are critical in managing the complexity of image acquisition, transfer, analysis, and interpretation in a standardized and blinded manner.

In conclusion, the clinical trial imaging market is experiencing sustained growth, fundamentally driven by the evolving needs of drug development. The convergence of targeted therapeutic modalities, the demand for objective biomarkers in chronic diseases, and the strategic investments from the biotech sector are cementing imaging's role as a critical success factor in clinical research. Future market evolution will be shaped by advancements in quantitative imaging biomarkers, the integration of artificial intelligence for enhanced data analysis, and the ongoing need for greater standardization across global research networks. For industry experts, the focus remains on leveraging imaging to improve trial efficiency, demonstrate definitive therapeutic value, and accelerate the delivery of new treatments to patients.

Key Benefits of this Report:

  • Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
  • Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
  • Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
  • Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
  • Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

  • Historical data from 2021 to 2025 & forecast data from 2026 to 2031
  • Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
  • Competitive Positioning, Strategies, and Market Share Analysis
  • Revenue Growth and Forecast Assessment of segments and regions including countries
  • Company Profiling (Strategies, Products, Financial Information, and Key Developments among others.)

Clinical Trial Imaging Market Segmentation

  • By Offerings
  • Solutions
  • Services
  • By Technique
  • MRI (Magnetic Resonance Imaging)
  • CT (Computed Tomography)
  • PET (Positron Emission Tomography)
  • Ultrasound
  • Others
  • By Application
  • Oncology
  • Cardiology
  • Gastroenterology
  • Neurology
  • Pediatrics
  • Others
  • By End-User
  • Hospitals & Clinics
  • Diagnostics Centers
  • Others
  • By Geography
  • North America
  • United States
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Others
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Thailand
  • Others

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

  • 2.1. Market Overview
  • 2.2. Market Definition
  • 2.3. Scope of the Study
  • 2.4. Market Segmentation

3. BUSINESS LANDSCAPE

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Porter's Five Forces Analysis
  • 3.5. Industry Value Chain Analysis
  • 3.6. Policies and Regulations
  • 3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. CLINICAL TRIAL IMAGING MARKET BY OFFERINGS

  • 5.1. Introduction
  • 5.2. Solutions
  • 5.3. Services

6. CLINICAL TRIAL IMAGING MARKET BY TECHNIQUE

  • 6.1. Introduction
  • 6.2. MRI (Magnetic Resonance Imaging)
  • 6.3. CT (Computed Tomography)
  • 6.4. PET (Positron Emission Tomography)
  • 6.5. Ultrasound
  • 6.6. Others

7. CLINICAL TRIAL IMAGING MARKET BY APPLICATION

  • 7.1. Introduction
  • 7.2. Oncology
  • 7.3. Cardiology
  • 7.4. Gastroenterology
  • 7.5. Neurology
  • 7.6. Pediatrics
  • 7.7. Others

8. CLINICAL TRIAL IMAGING MARKET BY END-USER

  • 8.1. Introduction
  • 8.2. Hospitals & Clinics
  • 8.3. Diagnostics Centers
  • 8.4. Others

9. CLINICAL TRIAL IMAGING MARKET BY GEOGRAPHY

  • 9.1. Introduction
  • 9.2. North America
    • 9.2.1. USA
    • 9.2.2. Canada
    • 9.2.3. Mexico
  • 9.3. South America
    • 9.3.1. Brazil
    • 9.3.2. Argentina
    • 9.3.3. Others
  • 9.4. Europe
    • 9.4.1. Germany
    • 9.4.2. France
    • 9.4.3. United Kingdom
    • 9.4.4. Spain
    • 9.4.5. Others
  • 9.5. Middle East and Africa
    • 9.5.1. Saudi Arabia
    • 9.5.2. UAE
    • 9.5.3. Israel
    • 9.5.4. Others
  • 9.6. Asia Pacific
    • 9.6.1. China
    • 9.6.2. India
    • 9.6.3. Japan
    • 9.6.4. South Korea
    • 9.6.5. Indonesia
    • 9.6.6. Thailand
    • 9.6.7. Others

10. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 10.1. Major Players and Strategy Analysis
  • 10.2. Market Share Analysis
  • 10.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 10.4. Competitive Dashboard

11. COMPANY PROFILES

  • 11.1. IXICO plc
  • 11.2. Resonance Health
  • 11.3. Radiant Sage LLC
  • 11.4. Medpace Holdings, Inc
  • 11.5. WCG Clinical
  • 11.6. Koninklijke Philips N.V.
  • 11.7. Median Technologies
  • 11.8. Perceptive
  • 11.9. Clario
  • 11.10. Qmenta

12. APPENDIX

  • 12.1. Currency
  • 12.2. Assumptions
  • 12.3. Base and Forecast Years Timeline
  • 12.4. Key Benefits for the Stakeholders
  • 12.5. Research Methodology
  • 12.6. Abbreviations